• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

ASPIRIN RCT Results: Low-Dose Aspirin in Early Pregnancy and Impact on Preterm Delivery and Perinatal Mortality

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Low-dose aspirin for early preeclampsia prevention appears to decrease preterm birth rates
  • Hoffman et al. (The Lancet, 2020) assessed whether daily low-dose aspirin early in pregnancy reduces the incidence of preterm delivery

METHODS:

  • Randomized, multi-country, double-masked, placebo-controlled trial (RCT)
  • Participants
    • Nulliparous women | Singleton pregnancy
    • Between 18 to 40 years (minors aged ≥14 years if permitted by individual ethics boards in the Democratic Republic of the Congo, Kenya, and Zambia)
    • Excluded if had medical conditions (e.g., diabetes or hypertension) or fetal anomalies identified
    • Ultrasound confirmed dates
  • Setting
    • Six countries (Low- and middle-income countries): India, Democratic Republic of the Congo, Guatemala, Kenya, Pakistan, and Zambia
  • Interventions
    • Low-dose aspirin (81 mg) daily
    • Placebo
  • Study design
    • Randomization 1:1, stratified by site
    • Aspirin or placebo started between 6w0d and 13w6d | Continued until 36w7days or delivery
    • Research staff, health providers, and patients were blinded to pill contents
  • Primary outcome
    • Incidence of preterm birth (<37 weeks)
  • Secondary outcomes
    • There were multiple predefined secondary outcomes including those related to maternal and neonatal morbidity and mortality
  • Data analysis
    • Incidence of preterm birth analyzed at or after 20 weeks (intention to treat)
    • Stratified by site
    • Relative risk (RR) estimates and associated confidence intervals were calculated
  • Serious adverse events: Assessed in all women who received ≥1 dose of drug or placebo

RESULTS:

  • A total of 11,976 women were enrolled
    • Low-dose aspirin: 5990 women
    • Placebo: 5986 women
    • 5780 women in the aspirin group and 5764 in the placebo group were included in the primary outcome analysis
  • Preterm birth was less frequent in the aspirin group (p=0.012)
    • Aspirin group: 11.6%
    • Placebo group: 13.1%
    • RR 0.89 (95% CI, 0.81 to 0.98)
  • For women in the aspirin group, the following perinatal complications were also reduced
    • Perinatal mortality
      • RR 0.86 (95% CI, 0.73 to 1.00; p=0.048)
    • Fetal loss (infant death >16 weeks’ gestation and <7 days postpartum)
      • RR 0.86 (95% CI, 0.74 to 1.00; p=0.039)
    • Early preterm delivery (<34 weeks)
      • RR 0.75 (95% CI, 0.61 to 0.93; p=0.039)
    • The incidence of women who delivered <34 weeks with hypertensive disorders of pregnancy
      • RR 0.38 (95% CI, 0.17 to 0.85; p=0.015)
  • Other adverse maternal and neonatal events did not show significant differences between the 2 groups

CONCLUSION:

  • For nulliparous women with singleton pregnancies in low- and middle-income countries, low-dose aspirin started early in pregnancy had a positive impact on pregnancy outcomes by reducing preterm labor and perinatal mortality
  • Authors recognize an important limitation of their study – they do not differentiate between iatrogenic and spontaneous preterm birth
    • Purposeful, as included centers may not have the capacity to determine cause
    • Most common reason for induced preterm birth would be hypertension and FGR
    • The authors state that

…ultimately, the decreases in preterm birth and perinatal mortality with low-dose aspirin therapy are the most meaningful outcomes to women and their children, regardless of the causative mechanism

Learn More – Primary Sources:

Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Try it Free »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

ASPRE Trial: A Combined Risk Algorithm and Use of Aspirin to Prevent Preterm Preeclampsia
Does Low Dose Aspirin Reduce the Risk of Spontaneous Preterm Birth?
Can Aspirin Decrease Risk of Placental Abruption and Antepartum Hemorrhage?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site